News Releases


2017 | 2016 | 2015 | Archive
Keyword Search
 
DateTitle 
10/04/17ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
Dementia-Related Psychosis Includes Psychosis in Patients with Alzheimer’s Disease, Dementia with Lewy Bodies, Parkinson’s Disease Dementia, Vascular Dementia, and Frontotemporal Dementia FDA Grants Breakthrough Therapy Designation to Pimavanserin for Dementia-Related Psychosis Conference Call to Be Held Today at 5:00 pm ET to Discuss Phase III Development Program SAN DIEGO--(BUSINESS... 
Printer Friendly Version
09/19/17ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
SAN DIEGO--(BUSINESS WIRE)--Sep. 19, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m. Eastern Time in New York City. A live webcast of... 
Printer Friendly Version
08/08/17ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
Second Quarter Net Sales Grew to $30.5 Million Including $3.6 Million From Transition to Sell-In Method of Accounting SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the sec... 
Printer Friendly Version
08/01/17ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2017, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter end... 
Printer Friendly Version
07/25/17ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
SAN DIEGO--(BUSINESS WIRE)--Jul. 25, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has been ranked 11th on Forbes Magazine’s 2017 list of the World’s Most Innovative Growth Companies. ACADIA is a biopharmaceutical company dedicated to developing and delivering innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. “We are pleased to be recognized by Forbes as a leader in i... 
Printer Friendly Version
05/09/17ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 9, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the first quarter ended March 31, 2017. “We’re very pleased with our strong start to 2017,” said Steve Davis, ACADIA’s President a... 
Printer Friendly Version
05/08/17ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
SAN DIEGO--(BUSINESS WIRE)--May 8, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16, 2017, at 10:00 a.m. Pacific Time in Las Vegas. A live webcast of ... 
Printer Friendly Version
05/02/17ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, May 9, 2017, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May 2, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March 31, ... 
Printer Friendly Version
03/30/17ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
Terrence O. Moore Retires as Chief Commercial Officer SAN DIEGO--(BUSINESS WIRE)--Mar. 30, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Michael J. Yang has joined ACADIA as Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds Terr... 
Printer Friendly Version
03/29/17ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017, at 10:40 a.m. Eastern Time in New York City. A live webca... 
Printer Friendly Version
02/28/17ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
NUPLAZID® Net Product Sales Grew to $12.0 Million in Fourth Quarter 2016 Executing on Broad Clinical Development Program in Alzheimer’s Disease Psychosis, Alzheimer’s Disease Agitation, Schizophrenia Inadequate Response, Negative Symptoms of Schizophrenia, and Major Depressive Disorder SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development an... 
Printer Friendly Version
02/27/17ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017, at 1:20 p.m. Eastern Time in Boston. A live webcast of ACADIA... 
Printer Friendly Version
02/21/17ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, February 28, 2017, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 21, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and yea... 
Printer Friendly Version
01/03/17ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, at 1:30 pm Pacific Time in San Francisco. A live webcast of ACADI... 
Printer Friendly Version